

Groundbreaking science. It's in our DNA.

Corporate overview

Genentech Inc., the founder of the biotechnology industry, has a quarter-century track-record of delivering on the promise of biotechnology. Today, Genentech is among the world's leading biotech companies, with multiple protein-based products on the market for serious or life-threatening medical conditions and over 30 projects in the pipeline. With its strength in all areas of the drug development process — from research and development to manufacturing and commercialization — Genentech continues to transform the possibilities of biotechnology into improved realities for patients.

Our mission is to be the leading biotechnology company, using human genetic information to discover, develop, manufacture, and commercialize biotherapeutics that address significant unmet medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of patients, the medical profession, our employees, and our communities, and to seeking significant returns to our stockholders based on the continual pursuit of scientific and operational excellence.

Research and development

As a biotherapeutics company, Genentech encourages its scientists to direct their research toward potential applications to medicine. At the same time, we encourage basic biomedical research and have a company culture that offers individual creativity and initiative among its researchers. As a result, our scientists have consistently published many important papers in prestigious journals and are among the top researchers in the world in terms of total citations. They have also secured more than 5,500 patents worldwide (with 6,000 pending) — an outstanding record in the industry.

The experience, diversity, and dedication of our research organization assures that Genentech will continue to play a significant role in discovering new treatments.

Genentech has a long-standing tradition of reinvesting a significant percentage of revenues back into research and development — a practice that has proved successful in transforming promising candidates into



Founders Research Center

important new products. Our development pipeline has never been more robust and promising. We are currently investigating additional applications for a number of existing products and continue to develop new molecules for a broad range of applications.

Our products

Genentech has an extensive track record in all phases of bringing new disease treatments to patients. With multiple biologic-based products on the market for serious or life-threatening medical conditions, Genentech has experience taking a drug from A to Z — transforming the seed of an idea in a lab into a novel therapy for a patient in need. Today, Genentech has one of the leading product portfolios in the biotech industry.

Our commitment to cancer and cancer research is demonstrated by the work of our oncology franchise. Genentech BioOncology is fundamentally transforming the way cancer is treated, with the goal of moving cancer toward a more manageable disease. Some of our groundbreaking developments include agents that treat the following:

- Colorectal cancer
- Breast cancer
- Lymphoma
- Lung cancer
- Pancreatic cancer

We have also developed multiple immunologic antibodies, agents applied to vascular medicine, and a number of specialty biotherapeutics.

In 2003, our upgraded Founders Research Center opened in South San Francisco, California. This 555,000 square-foot, \$85 million research facility houses specialized laboratories and state-of-the-art science equipment and accommodates over 600 worldclass scientists.

Contact us

To learn more about our facility and to schedule a visit, please see the details below.

CONTACT DETAILS

Corporate Headquarters
Genentech, Inc.
1 DNA Way
Founders Research Center
South San Francisco, CA 94080-4990
T: (650) 225-1000
F: (650) 225-6000

Genentech
IN BUSINESS FOR LIFE